<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36774721</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>160</Volume><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series.</ArticleTitle><Pagination><StartPage>114378</StartPage><MedlinePgn>114378</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2023.114378</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(23)00166-X</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with high mortality and morbidity rate affecting both upper and lower motor neurons (MN). Muscle force reduction, behavioral change, pseudobulbar affect, and cognitive impairments are the most common clinical manifestations of ALS. The main physiopathology of ALS is still unclear, though several studies have identified that oxidative stress, proteinopathies, glutamate-related excitotoxicity, microglial activation, and neuroinflammation may be involved in the pathogenesis of ALS. From 1995 until October 2022, only Riluzole, Dextromethorphan Hydrobromide (DH) with Quinidine sulfate (Q), Edaravone, and Sodium phenylbutyrate with Taurursodiol (PB/TUDCO) have achieved FDA approval for ALS treatment. Despite the use of these four approved agents, the survival rate and quality of life of ALS patients are still low. Thus, finding novel treatments for ALS patients is an urgent requirement. Masitinib, a tyrosine kinase inhibitor, emphasizes the neuro-inflammatory activity of ALS by targeting macrophages, mast cells, and microglia cells. Masitinib downregulates the proinflammatory cytokines, indirectly reduces inflammation, and induces neuroprotection. Also, it was effective in phase 2/3 and 3 clinical trials (CTs) by increasing overall survival and delaying motor, bulbar, and respiratory function deterioration. This review describes the pathophysiology of ALS, focusing on Masitinib's mechanism of action and explaining why Masitinib could be a promising actor in the treatment of ALS patients. In addition, Masitinib CTs and other competitor drugs in phase 3 CTs have been discussed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ketabforoush</LastName><ForeName>Arsh Haj Mohamad Ebrahim</ForeName><Initials>AHME</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chegini</LastName><ForeName>Rojin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barati</LastName><ForeName>Shirin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Saveh University of Medical Sciences, Saveh, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahmasebi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anatomy, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghisseh</LastName><ForeName>Bardia</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Student Research Committee, Arak University of Medical Sciences, Arak, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joghataei</LastName><ForeName>Mohammad Taghi</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faghihi</LastName><ForeName>Faezeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: faezefaghihi@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azedi</LastName><ForeName>Fereshteh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: azeditehrani.f@iums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>M59NC4E26P</RegistryNumber><NameOfSubstance UI="C526575">masitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Masitinib</Keyword><Keyword MajorTopicYN="N">Therapy</Keyword><Keyword MajorTopicYN="N">Tyrosine kinase inhibitor</Keyword></KeywordList><CoiStatement>Conflict of interest statement Authors declare no financial and non-financial conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>12</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36774721</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2023.114378</ArticleId><ArticleId IdType="pii">S0753-3322(23)00166-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>